Manipulating Nature – Why Big Pharma Loves the Power of Synthetic Cannabinoids
When you read “Big Pharma” and “Cannabinoids” in one sentence, one thing is certain: cannabis is on the move again to solve serious medical problems. Big Pharma will only focus on and work with one compound that it deems valuable and will use every mechanism in its arsenal to ensure maximum use of such a component.
What are synthetic cannabinoids?
Synthetic cannabinoids refer to molecules that bind to the same cannabinoids (THC and CBD) that are found in cannabis plants. They are compared to designer drugs that are sprayed or smoked on plant material and can be taken as a concentrated liquid in the UK and US. Why does Big Pharma prefer synthetic cannabinoids? First, let’s uncover the differences between “natural” and “synthetic” cannabinoids.
The differences between natural and synthetic cannabinoids
Natural cannabinoids are obtained and separated from natural sources such as the C. sativa plant and other types of biological species. While the synthetic cannabinoids are made from scratch in a laboratory with the chemical synthesis process using chemical precursors.
Some people consider synthetic cannabinoids to be “poor quality” when compared to their natural counterparts. However, Professor Edvinas Orentas, who works closely with Sanobiotec, claims that the concept of “poor quality” is neither a property of natural nor synthetic cannabinoids.
He went on to explain that at the molecular level there is no difference between a synthetically produced and a natural cannabinoid. Yes, there is a stigma around “synthetic” (it doesn’t just affect cannabinoids). Still, he believes the best way to remove such a stigma is to persist in educating the public about the values of synthetic cannabinoids that big drug companies take seriously.
The world currently thrives on technological innovations in support of natural sources. If natural cannabinoid is not available, it can lead to product shortages. Hence the reason why synthetic is gaining a lot of momentum is gaining traction.
The company Sanobiotec
To understand Big Pharma’s preference for synthetic cannabinoids, we need to turn to an established company responsible for this discovery. Sanobiotec focuses on the development of a broader spectrum of cannabinoid applications in the pharmaceutical and wellness sector.
They are interested in mainstream and rare cannabinoids, with a significant part of their work focusing on combining synthesis, natural extractions, and biosynthesis to create high quality products.
The company operates in the EU with excellent manufacturing processes, all in an analytical laboratory. You have discovered the valuable components of synthetic cannabinoids and the potential they contain and will accompany this discovery to the end.
Sanobitec needs a cannabinoid that can be accessed year-round, and synthetic cannabinoid offers that security, making it a highly valued preference. You can understand Big Pharma’s commitment to synthetic cannabinoids if you take full advantage of its benefits.
The benefits of synthetic cannabinoids
Synthetic cannabinoids can be made on a large scale, starting with cheap and straightforward chemicals, which means labor-intensive and land-intensive plating steps are eliminated. In addition, the quality and yield of the synthetic cannabinoid are more reproducible and are not subject to seasonal changes.
With natural cannabinoids, companies may have to wait for the plant to bloom during its season before gaining access to cannabinoids. However, since synthetic cannabinoid is made in the laboratory, you have access to it at all times.
In addition, some natural cannabis plants are exposed to pesticides and toxic chemicals, which also negatively affects the cannabinoid derived from such a plant. With synthetic cannabinoid, there are no worries or concerns about pesticides or harmful chemicals as it is made in the company’s safe facility.
Why large pharmaceutical companies prefer synthetic over natural cannabinoids
A small cannabis plant breeder can rely on the natural cannabinoid from plants because they only need a small amount. So he plants what he needs, and even if the plant is out of season, he can wait a while before planting again; This is on a small scale.
Big Pharma, on the other hand, is producing products on a large scale to reach millions of people and cannot afford to use an unreproducible cannabinoid. They will lose billions of dollars that should be made from sales if they do not have access to cannabinoid (which is the main ingredient in most of their cannabis products).
Synthetic cannabinoids are therefore very reproducible, making them an ideal and perfect choice for large pharmaceutical companies. The risk of biological contamination with synthetic cannabinoids is also lower than ever when using fully synthetic compounds.
Despite these advantages, it should be noted that both synthetic and natural cannabinoids are subject to strict, strict quality control requirements. The companies analyze their compounds for the same molecules. Therefore the test standards are the same.
However, natural cannabinoids are more likely to be at risk of pesticide contamination. Contamination is of great concern to large pharmaceutical companies who want to ensure that all products are safe for consumers before they are placed on the market.
The process of removing such impurities that cause cannabinoid contamination is also too difficult compared to a risk-free synthetic cannabinoid. As with any business, entrepreneurs always choose the option that saves costs and still offers the promise of quality.
Big Pharma is also concerned with sustainability and what works for them in the long run. Synthetic cannabinoids provide the stability they need to stay relevant in the market by consistently creating sought-after products.
As more companies conduct scientific research to determine the value of cannabinoids in the cannabis plant, Big Pharma is already exploring the possibilities of synthetic cannabinoids. While the natural cannabinoid remains a viable option, the synthetic cannabinoid is highly reproducible and desirable for large pharmaceutical companies.
Experts believe that the cannabinoids market will be saturated with some cannabinoids, especially CBD, and now it is time to explore all of this through synthetic measures. As Big Pharma takes the lead, they pave the way for other industries using cannabinoids, such as skin care companies.
SYTHETIC CANNABINOIDS AND THE FDA, READ MORE ..
YOUR GUIDE TO SYNTHETIC CANNABINOIDS FDA APPROVED!
FDA APPROVED CANNABIS MEDIA ALREADY ON THE MARKET?